Discovery Laboratories says that it will use the $1.9 million it has received from the National Heart, Lung, and Blood Institute (NHLBI) for a Phase 2a trial of Aerosurf inhaled KL4 surfactant that is already underway. The company had previously received $580,000 of the Fast Track Small Business Innovation Research (SBIR) grant, which it used for development of its capillary aerosol generator platform.
According to the company, patients are being enrolled into the Phase 2a escalating dose study, which should be completed by the third quarter of this year. The study will compare three doses of Aerosurf administered to premature infants with RDS who are receiving nasal continuous positive airway pressure (nCPAP) and premature infants with RDS getting nCPAP alone.
In May 2014, Discovery Labs announced that the appointment of Steve Simonson as VP, Clinical Development and Lawrence Weinstein as VP, Medical Device Development to support Aerosurf development.
Read the Discovery Labs press release.
